Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • January 16, 2025

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. PMID: 39817087; PMCID: PMC11734025.

Tags: amyloidosis, Cardiology/Epi, Outcomes, Publications, SGLT2 inhibitors, transthyretin amyloid cardiomyopathy

Demographics and Trends of Sudden Cardiac Death-Related Mortality in the United States, 1999 to 2022

Jaiswal V, Kumar D, Mashkoor Y, Latif F, Kanagala SG, Halder A, Jaiswal A, Bandyopadhyay D, Hajra A, Joshi A, Aronow WS, Fonarow GC. Demographics[...]

Disparities in Heart Failure Epidemiology, Diagnosis, Management, and Outcomes

Yan AR, Srivastava PK, Vucicevic D, Agarwal MA, Ziaeian B, Fonarow GC, Nsair A, Shahandeh N. Disparities in Heart Failure Epidemiology, Diagnosis, Management, and Outcomes.[...]

Skin-adaptive focused flexible micromachined ultrasound transducers for wearable cardiovascular health monitoring

Yuan J, Li Z, Zhao Y, Luo R, Qin S, Li J, Li M, Han G, Li Z, Zhao Z, Li J, Zhang S, Yuan[...]